newsfilter
← Latest News
GlobeNewswire·

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Joshua Pinto, Ph.D., appointed chief executive officer & member of the Board of Directors, while Paul L. Berns serves as Executive Chair
  • Doron Sagman, M.D., FRCPC, appointed as chief medical officer with over 20 years of clinical development experience
  • NMRA-215 NLRP3 inhibitor plans to submit IND in fourth quarter 2026 & initiate Phase 1 study by end of 2026 for obesity & cardiometabolic disease
  • NMRA-511 vasopressin 1a receptor antagonist data expected fourth quarter 2026 for Alzheimer's disease agitation, with Phase 2 initiation planned by end of 2026
  • NMRA-898 M4 positive allosteric modulator Phase 1 data expected second half of 2026 for schizophrenia
  • Cash & cash equivalents totaled $116.8 million as of June 30, 2026, funding operations into third quarter 2027
  • Research & development expenses were $29.3 million for second quarter 2026, down from $38.7 million in the prior year period
  • General & administrative expenses were $12.9 million for second quarter 2026, down from $15.3 million in the prior year period
  • Net loss reported at $43.1 million for second quarter 2026 compared to $52.7 million in the same period last year